Bristol Myers Squibb & Co. (NYSE:BMY) on Friday announced topline results from the Phase 3 INDEPENDENCE trial evaluating Reblozyl (luspatercept-aamt) with concomitant janus kinase inhibitor (JAKi ...

Bristol Myers and Pfizer said on Thursday they will start selling their blockbuster blood thinner, Eliquis, directly to cash-paying U.S. patients at a discount to its listed price as drugmakers ...

The drugmakers Bristol-Myers Squibb and Pfizer plan to sell the widely used blood thinner Eliquis directly to patients at a discounted cash price—a move that follows the Trump administration’s ...

Bristol Myers Squibb and Pfizer are launching a direct-to-patient program with 40% discount on Eliquis, reducing the monthly cost from $606 to $346 for eligible patients.

(Reuters) -US drugmakers Bristol Myers (NYSE: BMY) and Pfizer (NYSE: PFE) said on Thursday that they will make their blood thinner, Eliquis, available directly to cash-paying patients at ...

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. GSK has failed to win the backing of influential advisers to the US drugs regulator for a key blood cancer ...